• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025

    4/23/25 7:00:00 AM ET
    $MCRB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MCRB alert in real time by email

    CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on May 7, 2025 at 8:30 a.m. ET to discuss first quarter 2025 financial results and provide business updates.

    To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 4618787. To join the live webcast, please visit the "Investors and News" section of the Seres website at www.serestherapeutics.com.

    A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days.

    About Seres Therapeutics

    Seres Therapeutics, Inc. (NASDAQ:MCRB) is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. Seres led the successful development and approval of VOWST™, the first FDA-approved orally administered microbiome therapeutic, which was sold to Nestlé Health Science in September 2024. The Company is developing SER-155, which has received Breakthrough Therapy designation for the reduction of bloodstream infections in adults undergoing allo-HSCT and Fast Track designation for reducing the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT, and which has demonstrated a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT. SER-155 and the Company's other pipeline programs are designed to target multiple disease-relevant pathways and are manufactured from standard clonal cell banks via cultivation, rather than from the donor-sourced production process used for VOWST. In addition to allo-HSCT, the Company intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically vulnerable patient populations including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities. For more information, please visit www.serestherapeutics.com.

    Investor and Media Contact:  

    [email protected]

    Carlo Tanzi, Ph.D.

    Kendall Investor Relations

    [email protected]



    Primary Logo

    Get the next $MCRB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MCRB

    DatePrice TargetRatingAnalyst
    5/8/2025$6.00Buy → Neutral
    Chardan Capital Markets
    10/24/2024Neutral → Underweight
    JP Morgan
    6/26/2023$12.00Outperform
    Oppenheimer
    4/21/2023$7.00Neutral
    JP Morgan
    7/23/2021$42.00 → $29.00Buy
    Canaccord Genuity
    7/23/2021$30.00 → $16.00Buy
    Chardan Capital
    7/23/2021$36.00 → $18.00Outperform
    Oppenheimer
    7/23/2021$46.00 → $25.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $MCRB
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Seres Therapeutics Inc.

      SCHEDULE 13G/A - Seres Therapeutics, Inc. (0001609809) (Subject)

      6/6/25 10:03:48 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Seres Therapeutics Inc.

      S-8 - Seres Therapeutics, Inc. (0001609809) (Filer)

      5/7/25 4:06:14 PM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Seres Therapeutics Inc.

      10-Q - Seres Therapeutics, Inc. (0001609809) (Filer)

      5/7/25 10:00:20 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MCRB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting

      CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB) (Seres or the Company), a leading live biotherapeutics company, today announced the Company will be presenting new exploratory biomarker data from its SER-155 Phase 1b study in a poster session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 –June 3 in Chicago. The Company previously reported exploratory biomarker data from the SER-155 Phase 1b study showing evidence of improved intestinal epithelial barrier integrity and modulation of systemic inflammatory responses. The results are consistent with SER-155's intended therapeutic mechanisms to reduce the r

      5/27/25 7:00:00 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

      In line with recent FDA feedback, Seres expects to submit a Phase 2 study protocol to FDA in the coming weeks for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) for the treatment of hematological malignancies SER-155 Phase 1b placebo-controlled study exploratory translational biomarker data reinforce intended mechanisms of action, consistent with clinical results that showed a significant reduction (77% relative risk reduction) in BSIs, and support broader potential for Seres' live biotherapeutics to address inflammatory and immune diseases Seres advancing SER-155 strategic partnership discussions i

      5/7/25 7:00:00 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases

      CAMBRIDGE, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that it will present three related posters at the upcoming 2025 Digestive Disease Week (DDW) Conference being held May 3-6, 2025, in San Diego, CA. Seres previously reported exploratory translational biomarker data from its SER-155 Phase 1b study, which provided evidence supporting the intended therapeutic mechanisms. These included promoting intestinal epithelial barrier integrity to reduce the translocation of bacteria and inflammatory bacterial products into the bloodstream, as well as modulating systemic inflammatory responses. New resu

      4/29/25 7:00:00 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MCRB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Seres Therapeutics downgraded by Chardan Capital Markets with a new price target

      Chardan Capital Markets downgraded Seres Therapeutics from Buy to Neutral and set a new price target of $6.00

      5/8/25 8:27:44 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Seres Therapeutics downgraded by JP Morgan

      JP Morgan downgraded Seres Therapeutics from Neutral to Underweight

      10/24/24 6:25:19 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer resumed coverage on Seres Therapeutics with a new price target

      Oppenheimer resumed coverage of Seres Therapeutics with a rating of Outperform and set a new price target of $12.00

      6/26/23 7:26:19 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MCRB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • April 26, 2023 - FDA Approves First Orally Administered Fecal Microbiota Product for the Prevention of Recurrence of Clostridioides difficile Infection

      For Immediate Release: April 26, 2023 Today, the U.S. Food and Drug Administration approved Vowst, the first fecal microbiota product that is taken orally. Vowst is approved for the prevention of recurrence of Clostridioides difficile (C. difficile) infection (CDI) in individuals 18 years of age and older, following antibacterial treatment for recurrent CDI.  “Today’s approval provides patients and healthcare p

      4/26/23 6:04:21 PM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care